insights_auto
Why is 2359 down 2,19%?
Dive Deeperchevron_right
2359:HKG
WuXi AppTec Ord Shs H
HK$196,20
arrow_downward
-2,19%(-4,40) 1D
16 Okt., 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2359...
Open
HK$203,80
High
HK$209,00
Low
HK$185,00
Mkt. cap
544,52Â mjd
Avg. vol.
3,91Â m
Volume
10,16Â m
Dividend
1,22%
Quarterly dividend
HK$0,60
Ex-dividend date
04 Sep. 2026
P/E ratio
23,98
52-wk high
HK$219,20
52-wk low
HK$96,70
EPS
HK$8,18
No. of employees
36Â k
Open
HK$203,80
High
HK$209,00
Low
HK$185,00
Mkt. cap
544,52Â mjd
Avg. vol.
3,91Â m
Volume
10,16Â m
Dividend
1,22%
Quarterly dividend
HK$0,60
Ex-dividend date
04 Sep. 2026
P/E ratio
23,98
52-wk high
HK$219,20
52-wk low
HK$96,70
EPS
HK$8,18
No. of employees
36Â k
News stories
From web sources and news partners
ad-hoc-news.de
·
1 dag gelede
Morgan Stanley keeps target for WuXi AppTec stock at HKD 207.40
ad-hoc-news.de
·
2 dae gelede
Morgan Stanley backs 800-ton expansion for WuXi AppTec stock
ad-hoc-news.de
·
3 dae gelede
Morgan Stanley keeps HKD 207.40 target for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35,6Â k
Founded01 Des. 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn